Dr Simon Bomken
Clinical Fellow & Honorary Consultant
- Email: firstname.lastname@example.org
- Telephone: +44 (0) 191 208 4300
- Fax: +44 (0) 191 208 4301
- Address: Northern Institute for Cancer Research
Paul O'Gorman Building
Newcastle upon Tyne
2015 CCT Paediatrics (Paediatric Oncology)
2013 PhD, Newcastle University
2005 Membership of the Royal College of Paediatrics and Child Health, UK
2002 MBBS (Hons), Newcastle University
1999 BMedSci (Hons), Newcastle University
Academic Paediatric Association GBI
British Association for Cancer Research
Children's Cancer & Leukaemia Group (CCLG)
European Intergroup Collaboration for Childhood Non-Hodgkin Lymphoma (EICNHL)
International BFM Study Group - Genetic variation task force
Honours and Awards
2014 Lindau Nobel Laureate meeting alumnus, Royal Society nominee
2002 Mona McNaughton Prize - MBBS (Hons) final examination results 2002
1998 Wolfson Scholar - BMedSci (Hons)
Aggressive B cell lymphoma of childhood (focusing on Burkitt lymphoma and lymphoproliferative disorders in immunodeficient patients (primary immunodeficiency and post-transplant) - development of functional genomic screens and pre-clinical modelling
Childhood acute lymphoblastic leukaemia - characterisation of cancer propagating cells
Langerhans Cell Histiocytosis - Paediatric clinical service associated with Newcastle Human Dendritic Cell Laboratory (http://www.hudendritic.org/)
Together with Dr Vikki Rand and Dr Chris Bacon I run the Childhood Lymphoma Research Group within the NICR. My focus is on developing highly characterised pre-clinical models for the validation of novel therapeutic targets for Burkitt lymphoma. These models are suitable for the testing of new precision medicines, designed to improve rates of cure whilst reducing the extensive toxicity associated with current treatments for aggressive B cell lymphoma. I also work closely with UK and European colleagues (iBFM, EICNHL, ESID) to develop our understanding of development of lymphoid malignancy in children with inherited immune deficiency or DNA repair disorders.
I continue to work with Prof Olaf Heidenreich and Prof Josef Vormoor on projects aimed at understanding the genomic drivers of malignant B cell self-renewal and determinants of haematopoietic lineage specification. This work takes both a candidate approach and an unbiased, genome-wide approach to identify important elements of the genetic programmes allowing malignant cells to self-renew and propagate a malignancy. As lymphoid cells have an inherent potential for clonal expansion, this work looks to identify elements of the clonal expansion programme of lymphoid cells which are harnessed in lymphoid malignancy. It is therefore thought to be applicable to both B precursor and mature B cell diseases.
Funding - Current Projects
The Good Will Cause
North of England Children's Cancer Research Fund
Funding - Training
My current Clinical Fellow position is generously funded by the Sir Bobby Robson Foundation
ACF/ACL posts funded by NIHR
MRC Centenary Early Career Award
MRC Clinical Research Training Fellowship
I supervise undergraduate, masters and PhD students within the Northern Institute for Cancer Research, as well as providing clinical teaching for medical students within the Great North Children's Hospital.
I have contributed a chapter on clinical research to the recently published MRCPCH Science of Paedaitrics Mastercourse book for candidates of the Royal College of Paediatrics and Child Health membership exam. I am also currently revising chapters on childhood lymphoma and tumour lysis syndrome for the second edition of the Oxford University Handbook of Paediatric Haematology and Oncology.
- Offor UT, Bacon C, Gennery A, Reinhardt Z, Bomken S. Cardiac transplantation for congenital heart disease is associated with an increased risk of post-transplant lymphoproliferative disorder (PTLD) in children: a single centre experience. In: 58th Annual Scientific Meeting of the British Society for Haematology. 2018, Liverpool, United Kingdom: British Journal of Haematology.
- Ronceray A, Abla O, Barzilai-Birenboim S, Bomken S, Chiang AKS, Jazbec J, Kabickova E, Lazic J, Beishuizen A, Mellgren K, Tanaka F, Pillon M, Devalck C, Gouttenoire M, Makarova O, Burkhardt B, Attarbaschi A. Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. Pediatric Blood and Cancer 2018, 65(4), e26932.
- Elder A, Bomken S, Wilson I, Blair HJ, Cockell S, Ponthan F, Dormon K, Pal D, Heidenreich O, Vormoor J. Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia. Leukemia 2017, 31, 2577-2586.
- Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults. Blood 2017, Epub ahead of print.
- Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma. Haematologica 2017, 102(7), 1247-1257.
- Nanduri V, Michelagnoli M, Sudunagunta V, Vadgama B, Bigley V, Bomken S, Collin M, Holmes R, Visser J. National Web-Based Meetings Help to Identify Histiocytosis Patients with Refractory Disease or Sequelae who Need Individualised or Novel Treatment Strategies. In: 32nd Annual Meeting of the Histiocyte Society. 2016, Dublin, Ireland: John Wiley & Sons, Inc.
- Mellgren K, Attarbaschi A, Abla O, Alexander S, Bomken S, Bubanska E, Chiang A, Csóka M, Fedorova A, Kabickova E, Kapuscinska-Kemblowska L, Kobayashi R, Krenova Z, Meyer-Wentrup F, Miakova N, Pillon M, Plat G, Uyttebroeck A, Williams D, Wróbel G, Kontny U. Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases. Annals of Hematology 2016, 95(8), 1295-1305.
- Attarbaschi A, Carraro E, Abla O, Barzilai-Birenboim S, Bomken S, Brugieres L, Bubanska E, Burkhardt B, Chiang AK, Csoka M, Fedorova A, Jazbec J, Kabickova E, Krenova Z, Lazic J, Loeffen J, Mann G, Niggli F, Miakova N, Osumi T, Ronceray L, Uyttebroeck A, Williams D, Woessmann W, Wrobel G, Pillon M. Non-Hodgkin's lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica 2016, 101(10).
- Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C. The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. Blood 2016, 127(16), 1998-2006.
- Bomken S, Haigh S, Bown N, Carey P, Wood K, Windebank K. Cutaneous B-Lymphoblastic Lymphoma With IL3/IgH Translocation Presenting With Hypereosinophilia and Acute Endocarditis. Pediatric Blood & Cancer 2015, 62(6), 1055-1057.
- Elder A, Blair H, Dormon K, Bomken S, Cockell SJ, Heidenreich O, Vormoor J. High Abundance of Acute Lymphoblastic Leukaemia Founder Clones Does Not Translate to Functional Heterogeneity. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
- Bomken S, Skinner R. Second Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in Childhood. Children 2015, 2(2), 146-173.
- Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair HJ, Vormoor J, Ottmann O, Ganser A, Pich A, Hilfiker-Kleiner D, Heidenreich O, Eder M. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia 2014, 28, 554-565.
- Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, Stanulla M, Schrappe M, Hall AG, Heidenreich O, Vormoor J. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Molecular Medicine 2013, 5(1), 38-51.
- Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H, Bacon CM, Vormoor J, Heidenreich O. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia 2013, 27(3), 718-721.
- Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow LJ, Fordham SE, Forster VJ, Jackson G, Bomken S, Jones G, Allan JM. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 2012, 119(1), 196-205.
- Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, Bomken S, Vormoor J, Hall A, Irving J. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2012, 51(3), 250-256.
- Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. British Journal of Cancer 2010, 103(4), 439-445.
- le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving JAE, Stam R, Shultz L, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor HJ. In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties. Cancer Cell 2008, 14(1), 47-58.